Please try another search
For the three months ended 31 March 2016, GlobeImmune Inc revenues decreased 21% to $943K. Net loss decreased 45% to $862K. Revenues reflect Manufacturing services decrease from $161K to $0K, Collaboration license and services decrease of 8% to $943K. Lower net loss reflects Costs of collaboration license and servi decrease of 44% to $515K (expense), General and administrative decrease of 22% to $933K (expense).
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Revenue | 0.94 | 1.05 | 2.94 | 1.28 |
Gross Profit | 0.94 | 1.05 | 2.92 | 1.17 |
Operating Income | -0.86 | -0.8 | 0.89 | -1.3 |
Net Income | -0.86 | -0.8 | 0.89 | -1.3 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Total Assets | 9.77 | 11.51 | 13.21 | 13.54 |
Total Liabilities | 7.62 | 8.52 | 9.46 | 10.7 |
Total Equity | 2.15 | 2.99 | 3.75 | 2.84 |
Period Ending: | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 |
---|---|---|---|---|
Period Length: | 0 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -1.21 | -7.13 | -5.72 | -4.41 |
Cash From Investing Activities | 0 | 0.22 | 0.2 | -0.03 |
Cash From Financing Activities | 0 | 0 | 0 | |
Net Change in Cash | -1.21 | -6.91 | -5.52 | -4.45 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review